Objective: To observe the effect and safety of Xiaozhi particles, integrated taohong Siwu tang and Erchen tang and Xuezhikang capsule in treating hyperlipidaemia (HLP) associated with highly active antiretroviral therapy (HAART).
Method: In the multi-centered, randomized controlled clinical study, 180 hyperlipidaemia associated with highly active antiretroviral therapy cases were divided into the treatment group treated by Xiaozhi particles, integrated Taohong Siwu tang and Erchen tang, and the control group treated by Xuezhikang capsule. The treatment course was 12 weeks. The total cholesterol (Tch), triglyceride (TG), low density lipoprotein (LDL) and high-density lipoprotein(HDL) were observed.
Result: After 12 weeks, compared with Xuezhikang capsule, the change difference of Tch, LDL, HDL in the Chinese traditional medicine formula groups of patients is significant (P < 0.05), the change of the TG has no significant difference. The effect of Tch, LDL in Xuezhikang capsule groups is better than in traditional Chinese medicine formula group,but the effect of HDL in traditional Chinese medicine formula group is better than in Xuezhikang capsule groups.
Conclusion: Integrated Taohong Siwu tang and Erchen tang, Xiaozhi particles and Xuezhikang capsule can be used to control the hyperlipidaemia associated with highly active antiretroviral therapy as one of the main Chinese native medicine preparation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Clinical comprehensive evaluation of Jiangzhi Tongluo Soft Capsules for treating hyperlipidemia (syndrome of blood stasis and Qi stagnation)].
Zhongguo Zhong Yao Za Zhi
October 2024
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
This study provides a systematic review of existing evidence concerning the efficacy of Jiangzhi Tongluo Soft Capsules(JTSC) in treating hyperlipidemia(syndrome of blood stasis and Qi stagnation), following the Guidelines for clinical evidence and value assessment of drugs. The qualitative and quantitative methods were integrated, including questionnaire surveys, evidence-based medicine, and pharmacoeconomic evaluation. Multi-criteria decision analysis(MCDA) model was used for comprehensive assessment of the clinical evidence and value of JTSC for hyperlipidemia in "6+1" dimensions: safety, effectiveness, cost-effectiveness, innovation, suitability, accessibility, and traditional Chinese medicine(TCM) characteristics.
View Article and Find Full Text PDFEvidence mapping was performed to review the clinical trials and systematic reviews about the treatment of hyperlipidemia with Chinese patent medicines in recent ten years. A total of 387 clinical studies and 18 systematic reviews/Meta-analysis involving 45 Chinese patent medicines commonly used in the treatment of hyperlipidemia in recent ten years were retrieved from Chinese and English academic publication databases. The article information was extracted by reading the abstract and full text, and the evidence of publication trend, combined medication, intervention course, complications, and outcome indicators was sorted out.
View Article and Find Full Text PDFEffects of the combination of red yeast rice-containing commercial Chinese polyherbal preparation with statins for dyslipidemia: a systematic review and meta-analysis.
Front Pharmacol
July 2024
Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Background: Significant challenges are associated with the pharmacological management of dyslipidemia, an important risk factor for cardiovascular disease. Limited reliable evidence exists regarding the efficacy of red yeast rice (RYR)-containing commercial Chinese polyherbal preparation (CCPP), despite their widespread use in China.
Purpose: We aimed to investigate the efficacy of RYR-containing CCPPs combined with statins in treating dyslipidemia.
[Network Meta-analysis of Chinese patent medicine in treatment of heart failure with preserved ejection fraction].
Zhongguo Zhong Yao Za Zhi
February 2024
Heart Center of the First Affiliated Hospital, Henan University of Chinese Medicine Zhengzhou 450000, China.
This study systematically evaluated the efficacy and safety of different Chinese patent medicines combined with conventional western medicine in the treatment of heart failure with preserved ejection fraction(HFpEF) and ranked for the drug selection. Randomized controlled trial(RCT) on Chinese patent medicines in treatment of HFpEF were obtained from the CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, EMbase, Web of Science, and other databases from the inception to October 9, 2022. The included RCT was quantitatively analyzed using gemtc and rjags packages of R software for the network Meta-analysis.
View Article and Find Full Text PDFEnhancing quality evaluation in traditional Chinese medicine: Utilizing dual wavelength fusion fingerprint, electrochemical fingerprint, and DSC fingerprint.
J Chromatogr A
May 2024
College of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103 110032, Shenyang 110016, China; Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, College of Pharmacy, Jinan University, Guangzhou 510632, China. Electronic address:
Developing a reliable and effective quality evaluation system for traditional Chinese medicine (TCM) is both challenging and crucial for its advancement. This study employs fingerprinting techniques to establish precise and comprehensive quality control for TCM, taking Xuezhikang capsules as an example and aiming to facilitate the internationalization of TCM. The "double wavelength absorption coefficient ratio fingerprint" and "Reliability theory" are developed to determine the fingerprint peak purity and fingerprint reliability respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!